Venclexta, meanwhile, is already approved in two time-limited treatment regimens for CLL, and AMPLIFY is one of the first large-scale trials to combine BTK and BCL2 agents with a fixed duration.

Equities research analysts at StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a report issued on Sunday. The brokerage set a “sell” rating on ...

Research analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX – Get Free Report) in a research report issued on Friday. The firm set a “hold” rating on the ...

Tools, resources, and support for living with osteoporosis.